Hideki Garren, M.D., Ph.D.,
EVP, COO, CSO co-founded Bayhill in 2001 and has served as our Vice President of Research from 2005 to 2008, and prior to that served as our Director of Research from 2001 to 2005. Since 2003, Dr. Garren has been a member of the adjunct clinical faculty in the Department of Neurology at Stanford University School of Medicine. Dr. Garren received a B.S. from the California Institute of Technology, a Ph.D. in Molecular Biology from the University of California, Los Angeles, Molecular Biology Institute, and an M.D. from the University of California, Los Angeles, School of Medicine.
Robert S. King, Ph.D. has served as our
Vice President of Manufacturing since October 2006. From 2004 to 2006, he was Vice President of Product Development and Manufacturing at Rinat Neuroscience Corporation, a division of Pfizer Global Research and Development. From 1993 to 2003, Dr. King served in a series of positions of increasing responsibility in the areas of Process and Product Development, Manufacturing and Technical Operations at Millennium Pharmaceuticals, Inc.’s South San Francisco office and COR Therapeutics, Inc., which merged with Millennium Pharmaceuticals, Inc. in 2002. From 1991 to 1993, Dr. King served in various pharmaceutical and process research roles of increasing responsibility at Scios, Inc., formerly California Biotechnology, Inc. From 1988 to 1991, he served in various device development and sales/marketing roles of increasing responsibility at Molecular Devices Corp. Dr. King was also an adjunct professor in Chemical Engineering at San Jose State University from 1991 to 1992 and served on the Advisory Board for the San Jose State Masters in Biotechnology program from 2003 to 2005. Dr. King received a B.S. in Chemical Engineering from the University of Washington, Seattle and a Ph.D. in Chemical Engineering from the University of California, Berkeley.
Kwang S. Lee is a Certified Public Account who has served as our
Senior Director of Finance and Corporate Controller since July 2007. He has held various positions within corporate finance and accounting throughout his 15 year career focusing on financial strategy, budgeting, public reporting, and financial controls. Prior to joining Bayhill, he held managerial positions at MeeVee, Inc., Perlegen Sciences, and Genitope Corporation, where he was part of the finance team responsible for transitioning the company from a start up through its IPO. He holds a BS in Economics from the Cal Polytechnic State University at San Luis Obispo and is a graduate of the Lucas School of Business at San Jose State University.
Michael Leviten, Ph.D. joined Bayhill in 2003 as a Senior Scientist and has served as
Director of Molecular Biology since 2005. Prior to joining Bayhill, he was a Senior Scientist at Deltagen Inc. Dr. Leviten received his B.A. from Harvard University, a Ph.D. in Biology from UC San Diego, and was a postdoctoral fellow in the Department of Molecular and Cellular Biology at U.C. Berkeley.
Joanne M. Quan, M.D. has served as our
Vice President of Clinical and Regulatory Affairs since November 2008. From 2005 to 2008, Dr. Quan was Senior Director, Clinical Development at Alza Corporation (Johnson and Johnson). Dr. Quan held various positions in Clinical Research at Genentech from 2000 to 2005 and at PathoGenesis Corporation from 1996 to 2000. Dr. Quan completed her training in Pulmonary-Critical Care Medicine at the University of Washington, Seattle and Internal Medicine at Massachusetts General Hospital. Dr. Quan received a B.A. from the University of California, Berkeley and an M.D. from the Stanford University School of Medicine.
Nanette Solvason, Ph.D. joined Bayhill in 2001 and has held multiple positions within the company including Senior Scientist, Director of Immunology, and
Vice President of Immunology . Prior to joining Bayhill, Dr. Solvason worked at Eos Biotechnology, Inc., Corixa Corporation and Anergen, Inc. She received her B.S., M.S. and Ph.D. from the University of Alabama in Birmingham, and was a post doctoral fellow at DNAX Research Institute.
